Zydus Pharmaceuticals receives USFDA nod to market OCD treatment drug

Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market Clomipramine Hydrochloride capsules, used to treat obsessive-compulsive disorder (OCD).

The company has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 25 mg, 50 mg and 75 mg, Zydus Cadila said in a BSE filing.

The company will produce the drug at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Clomipramine hydrochloride capsule is used to treat the obsessive compulsive disorder, which is characterised by uncontrollable, re-occurring thoughts and behaviours.

The company has more than 180 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd.

Shares of Cadila Healthcare, the listed entity of the group, were up 1.68 per cent at Rs 432.05 on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel